Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 109Neoplasms 99Lung Neoplasms 60Colorectal Neoplasms 45Prostatic Neoplasms 40Carcinoma, Non-Small-Cell Lung 39Pancreatic Neoplasms 33Melanoma 31Head and Neck Neoplasms 27Neoplastic Cells, Circulating 25Ovarian Neoplasms 24Uterine Cervical Neoplasms 20Sarcoma 19Multiple Myeloma 19Glioma 19Colonic Neoplasms 19Carcinoma, Hepatocellular 17Leukemia, Myeloid, Acute 16Neoplasm Metastasis 15Squamous Cell Carcinoma of Head and Neck 14Lymphoma 14Glioblastoma 14Esophageal Neoplasms 14Endometrial Neoplasms 14Leukemia 12Kidney Neoplasms 11Hematologic Neoplasms 11Gastrointestinal Neoplasms 11Carcinoma, Renal Cell 11Myelodysplastic Syndromes 10

Interventions

Radiotherapy 6Doxorubicin 5Nivolumab 4pembrolizumab 3Sunitinib 3Ifosfamide 3Gemcitabine 3Docetaxel 3pazopanib 2Radiation Dose Hypofractionation 2Radiation 2Methotrexate 2Ipilimumab 2Cisplatin 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1temsirolimus 1spartalizumab 1sintilimab 1ribociclib 1regorafenib 1pegfilgrastim 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1itacitinib 1fludarabine 1eribulin 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Histiocytoma, Malignant Fibrous × Blood Specimen Collection × Clear all
NCT03946943 2019-07-10

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

The First Hospital of Jilin University

Phase 2 Unknown
25 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡